AMG.DE • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold AMG.DE in your mock portfolio yet.
With a PE ratio of 26.57 and EPS of 10.89, Amgen is priced at a premium to many mature pharma peers, implying the market expects steady earnings but not hyper‑growth. The valuation appears reasonable for a large-cap biotech with a solid earnings base, but without additional data on recent revenue and margin trends, the picture is more steady than clearly accelerating.
The stock is trading at €289.35, up 3.2% over the last month and comfortably above its 200-day moving average of €259.76, indicating a positive intermediate trend. However, the RSI at 70.23 signals overbought conditions, suggesting near-term upside may be limited and a consolidation or pullback is possible.
Alternative data for Amgen are broadly stable to modestly positive, with steady hiring, solid web traffic, and incremental growth across most social channels. The lack of strong growth or contraction in these indicators points to a steady business environment rather than a major inflection.
Amgen’s current profile appears balanced: a solid earnings base with a premium but not extreme valuation, a stock in a healthy uptrend that is technically overbought, and alternative data that are broadly stable with modest positive signals. This combination supports a neutral view, with the stock looking more like a steady compounder than a clear near-term breakout or breakdown candidate.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: